Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711419 | 0.82 | VNN1 (0.39) | EPHX2VNN1EPHX1 | |
| SCHEMBL2428114 | 0.81 | HPGD (0.47) | EPHX2VNN1ALDH1A1 | |
| SCHEMBL18701928 | 0.79 | DPP4 (0.40) | VNN1ALDH1A1CYP3A4CYP2C9SLC9A1 | |
| SCHEMBL12283718 | 0.79 | EPHX2 (0.41) | EPHX2EPHX1CYP3A4CYP2C9SLC9A1 | |
| SCHEMBL13245899 | 0.78 | EPHX2 (0.49) | EPHX2ALDH1A1EPHX1 | |
| SCHEMBL21655193 | 0.78 | EPHX2 (0.49) | EPHX2ALDH1A1EPHX1 | |
| SCHEMBL2422078 | 0.78 | VNN1 (0.40) | VNN1EPHX1CYP2C9 | |
| SCHEMBL15579770 | 0.78 | EPHX2 (0.40) | EPHX2EPHX1CYP3A4CYP2C9SLC9A1 | |
| SCHEMBL12510683 | 0.77 | EPHX2 (0.47) | EPHX2ALDH1A1EPHX1CYP3A4CYP2C9 | |
| SCHEMBL12876398 | 0.76 | EPHX2 (0.50) | EPHX2ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374802-B1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | EPHX2 2594/4885VNN1 1579/4885ALDH1A1 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.